Sugi Predict

Sugi Predict / Compounds / SCHEMBL4298060

SCHEMBL4298060

SCHEMBL4298060

CCN(CC)[C@@H](CCCCN)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 1/20 0.48
▸ RNPEP Q9H4A4 1/20 0.47
▸ CPB2 Q96IY4 6/20 0.45
▸ GABRR1 P24046 2/20 0.38
▸ FOLH1 Q04609 1/20 0.38
▸ GRIK1 P39086 2/20 0.37
▸ GRIK2 Q13002 2/20 0.37
▸ SLC1A2 P43004 1/20 0.37
▸ SLC1A1 P43005 1/20 0.37
▸ EPOR P19235 1/20 0.36
▸ GNAI3 P08754 1/20 0.36
▸ GNAO1 P09471 1/20 0.36
▸ GNAI1 P63096 1/20 0.36
▸ CYP2D6 P10635 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ SLC6A5 Q9Y345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298056 1.00 GSR (0.48) GSRRNPEPCPB2GABRR1FOLH1
SCHEMBL7281760 0.94 CPB2 (0.42) GSRRNPEPCPB2GABRR1GRIK1
SCHEMBL7281767 0.94 CPB2 (0.42) GSRRNPEPCPB2GABRR1GRIK1
SCHEMBL28611975 0.90 GPR84 (0.40) GRIK1GRIK2SLC1A2SLC1A1
SCHEMBL28621283 0.90 GSR (0.43) GSRRNPEPCPB2GABRR1FOLH1
Propylamine SCHEMBL11556581 0.87 GRIK1 (0.47) GRIK1GRIK2SLC1A2SLC1A1GNAI3
SCHEMBL28471628 0.87 NOD1 (0.44) GSRRNPEPCPB2GRIK1GRIK2
SCHEMBL28619664 0.86 HTR2A (0.37) GRIK1GRIK2SLC1A2SLC1A1
SCHEMBL4300233 0.85 GSR (0.46) GSRRNPEPCPB2FOLH1GRIK1
SCHEMBL4300231 0.85 GSR (0.46) GSRRNPEPCPB2FOLH1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025082461-A1 POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 优洛生物(上海)有限公司 2025-04-24 — — WO disclosed
EP-4518905-A1 IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES Seagen Inc. (US) 2025-03-12 — — EP disclosed
US-12162955-B2 CBX8 chromdomain inhibitors and the uses thereof PURDUE RESEARCH FOUNDATION (US) 2024-12-10 — — US disclosed
WO-2024108227-A1 CBX2 INHIBITORY COMPOUNDS FOR TREATING HIGH GRADE SEROUS OVARIAN CANCER THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2024-05-23 — — WO disclosed
WO-2024081302-A1 LIGAND-DIRECTED COVALENT MODIFICATION OF AMINO ACID SIDE CHAINS USING CYCLIC IMINE MANNICH ELECTROPHILES PURDUE RESEARCH FOUNDATION (US) 2024-04-18 — — WO disclosed
US-20240036055-A1 Multiplexed DiLeu-Biotin-Azide (DBA) Tag Enabled Isobaric Tandem Orthogonal Proteolysis Activity-Based Protein Profiling (isoBOP-ABPP) Platform For High-Throughput Quantitative Pan-PTM Analysis WISCONSIN ALUMNI RESEARCH FOUNDATION 2024-02-01 — — US disclosed
CN-117460710-A Amino acid cationic lipid 厦门赛诺邦格生物科技股份有限公司 2024-01-26 — — CN disclosed
WO-2023215740-A1 IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES SEAGEN INC. (US) 2023-11-09 — — WO disclosed
US-20230257421-A1 CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-08-17 — — US disclosed
US-11566046-B2 CBX8 chromdomain inhibitors and the uses thereof PURDUE RESEARCH FOUNDATION (US) 2023-01-31 — — US disclosed
US-20040086943-A1 Coupling agent containing secordary amide groups ROCHE DIAGNOSTICS OPERATIONS, INC. 2004-05-06 — — US disclosed
EP-1364208-A2 CONJUGATES OF DEFINED STOICHIOMETRY Roche Diagnostics GmbH (DE) 2003-11-26 — — EP disclosed
EP-1327146-A2 COMPOUNDS WITH A BRANCHED LINKER Roche Diagnostics GmbH (DE) 2003-07-16 — — EP disclosed
EP-1245956-A1 Conjugates of defined stoichiometry Roche Diagnostics GmbH (DE) 2002-10-02 — — EP disclosed
WO-2002027317-A2 CONJUGATES OF DEFINED STOICHIOMETRY ROCHE DIAGNOSTICS GMBH (DE) 2002-04-04 — — WO disclosed
WO-2002027315-A2 COMPOUNDS WITH A BRANCHED LINKER ROCHE DIAGNOSTICS GMBH (DE) 2002-04-04 — — WO disclosed
EP-0720614-B1 METAL COMPLEXES WITH CHARGED LINKER ROCHE DIAGNOSTICS GMBH (DE) 2000-05-24 — — EP disclosed
US-5958783-A AS LUMINESCENT MARKERS IN IMMUNOASSAYS AND HYBRIDIZATIONS; IMPROVED STABILITY AND RECOVERY OF CONJUGATES, INCREASED QUANTUM YIELD ROCHE DIAGNOSTICS GMBH (DE) 1999-09-28 — — US disclosed
EP-0720614-A1 METAL COMPLEXES WITH CHARGED LINKER Roche Diagnostics GmbH (DE) 1996-07-10 — — EP disclosed
WO-1996003409-A1 METAL COMPLEXES WITH CHARGED LINKER BOEHRINGER MANNHEIM GMBH (DE) 1996-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257421-A1 CBX8 CHROMDOMAIN INHIBITORS AND THE USES THEREOF CBX8, CBX3, CBX2 GSR 4586/4885RNPEP 2784/4885CPB2 1749/4885
US-11566046-B2 CBX8 chromdomain inhibitors and the uses thereof CBX8, CBX3, CBX2 GSR 4586/4885RNPEP 2784/4885CPB2 1749/4885
US-20040086943-A1 Coupling agent containing secordary amide groups PAICS, BRDT, ERBB2 GSR 3250/4885RNPEP 689/4885CPB2 1696/4885
US-12162955-B2 CBX8 chromdomain inhibitors and the uses thereof CBX8, CBX3, CBX2 GSR 4586/4885RNPEP 2784/4885CPB2 1749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.